Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.3.16 (
calcineurin
)
17,112
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Activated/uninhibited
calcineurin
is both necessary and sufficient to induce cardiac hypertrophy, a condition that often leads to dilated cardiomyopathy, heart failure, and sudden cardiac death. We expressed constitutively active
calcineurin
in the adult heart of Drosophila melanogaster and identified enlarged cardiac chamber dimensions and reduced cardiac contractility. In addition, expressing constitutively active
calcineurin
in the fly heart using the Gal4/UAS system induced an increase in heart wall thickness. We performed a targeted genetic screen for modifiers of
calcineurin
-induced cardiac enlargement based on previous
calcineurin
studies in the fly and identified
galactokinase
as a novel modifier of
calcineurin
-induced cardiomyopathy. Genomic deficiencies spanning the
galactokinase
locus, transposable elements that disrupt
galactokinase
, and cardiac-specific RNAi knockdown of
galactokinase
suppressed constitutively active
calcineurin
-induced cardiomyopathy. In addition, in flies expressing constitutively active
calcineurin
using the Gal4/UAS system, a transposable element in
galactokinase
suppressed the increase in heart wall thickness. Finally, genetic disruption of
galactokinase
suppressed
calcineurin
-induced wing vein abnormalities. Collectively, we generated a model for discovering novel modifiers of
calcineurin
-induced cardiac enlargement in the fly and identified
galactokinase
as a previously unknown regulator of
calcineurin
-induced cardiomyopathy in adult Drosophila.
...
PMID:Galactokinase is a novel modifier of calcineurin-induced cardiomyopathy in Drosophila. 2508 66
